611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
When Is It Time for a Knee Replacement?AHA News: Death Rates From Tears In This Major Heart Artery Are Rising, Especially Among Women, Black AdultsOmicron COVID Causing Severe Croup in Young Children'Zapping' Air Passages May Bring Relief for Severe AsthmaModerna Asks FDA to Approve Second Booster for All AdultsNew Tick-Borne Virus Is Spreading Across U.S.Memory Issues Plague Long COVID PatientsCOVID Vaccine Won't Cause Rare Neuro Events, But COVID Infection CouldTriglycerides a Stroke Danger, Even With Statin TreatmentIt Can Take Weeks for Some Patients With Severe COVID to Recover ConsciousnessOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaBreathing Dirty Air Could Raise Your Odds for Rheumatoid ArthritisPalliative Care Crucial After Severe Stroke, But Many Patients Miss OutMammograms Can Also Highlight Heart Risks: StudyPfizer Asks FDA to Approve Second Booster for SeniorsEven a Little Light in Your Bedroom Could Harm HealthMental Issues Can Linger More Than a Year After Severe COVIDRise in U.K. COVID Cases Closely Watched by U.S. Health OfficialsLong COVID May Bring Long-Term Lung DamageNew Malaria Treatment Gets First Approval for Use in ChildrenWarming World Means More Cases of Dangerous Low-Salt ConditionAbout 1 in 6 U.S. Couples Disagrees on COVID VaccinationCOVID Meds Appear to Work Against BA.2 Omicron Variant‘Deltacron’ Variant Rare and Not a Major ConcernCould Depression Make Dry Eye Worse?When Will Americans With Diabetes Get Relief From High Insulin Prices?COVID's Global Death Toll May Be 3 Times Official NumbersDrug Could Be Non-Antibiotic Alternative to Treat UTIsFlu Vaccine No Match for Circulating Variants This SeasonLymphedema in Legs Strikes 1 in 3 Female Cancer SurvivorsScience Brings Shortcut to Spotting 50 Rare Genetic DiseasesU.S. Airplane, Train and Transit Mask Mandates Extended to April 18Man Who Received First Pig Heart Transplant Has DiedPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Could a Stool Test Help Spot Pancreatic Cancer?Upcoming Surgery Worry You? Poll Says You're Not AloneHalf of Americans Live With Legacy of Childhood Lead PoisoningIn Reversal, WHO Now Supports COVID BoostersLooking to Neanderthals to Explain Today's Lower Back PainWhat's More Accurate, Blood Pressure Readings at Home or Doctor's Office?Begin Now to Protect Your Heart as Clocks 'Spring Forward'Brain Changes May Fuel 'Long COVID' Anxiety, ConfusionAHA News: Break Up Binge-Watching by Taking a StandHow COVID-19 Can Change the BrainHeart Defects Could Raise Odds for Severe COVID-196 Healthy Steps to Preventing Colon CancerAHA News: These Three Risk Factors May Have the Biggest Impact on Dementia CasesU.S. Surgeon General Investigates COVID-19 MisinformationLong or Irregular Periods May Put a Woman's Liver at RiskCould Your Blood Type Make COVID Worse?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

COVID Meds Appear to Work Against BA.2 Omicron Variant


HealthDay News
Updated: Mar 14th 2022

new article illustration

MONDAY, March 14, 2022 (HealthDay News) -- A number of COVID medications have proven their mettle against the "stealth" BA.2 Omicron variant in lab tests, but it's not clear how effective they would be in real-world use, researchers report.

Some evidence suggests that BA.2 can spread more quickly than the already highly contagious earlier BA.1 variant.

In lab experiments using non-human primate cells, researchers tested seven monoclonal antibodies, three combinations of antibodies, and three antiviral treatments against the BA.2 variant. Most approved antibody treatments are a combination of different antibodies.

The antiviral therapies remdesivir, Merck's molnupiravir and the active ingredient in Pfizer’s Paxlovid pill (nirmatrelvir) worked against the BA.2 variant, according to the study published March 9 in the New England Journal of Medicine.

According to the findings, the most effective antibody treatment against the BA.2 variant was AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), which is approved in the United States to help prevent COVID infection in people vulnerable to severe disease.

Antibody treatments form Regeneron and GlaxoSmithKline were more effective against BA.2 than they are against the BA.1 variant, but were not as strong against BA.2 as they were against earlier versions of the virus.

The researchers also found that Lilly's antibody cocktail of etesevimab and bamlanivimab did not neutralize the BA.2 virus at common dosages.

"The bottom line is we have antibodies that appear to be more effective against BA. 2 compared with BA.1 or BA.1.1. That's good news, but we don’t know whether what we found in the lab translates into clinical settings," said study leader Yoshihiro Kawaoka, a virologist at the School of Veterinary Medicine at the University of Wisconsin-Madison and the University of Tokyo.

"We also tested clinically available antiviral compounds, and they are all highly efficacious," he added in a University of Wisconsin news release.

Current COVID treatments tend to be less effective against new variants than against the original virus because they were designed and tested against earlier versions of the virus, the study authors noted.

It takes months to create and test treatments against new variants of the virus.

More information

There's more on COVID-19 variants at the U.S. Centers for Disease Control and Prevention.

SOURCE: University of Wisconsin-Madison, news release, March 10, 2022